Jubilant Pharmova Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹2,122Cr
- +16.5% YoY
- +7.9% QoQ
- Net profit
- ₹56Cr
- −44.6% YoY
- −53.3% QoQ
- Margin
- 14%
- −2 pp YoY
- −3 pp QoQ
Guidance rank: #73 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Jubilant Pharmova Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3’FY26 Total Income: Rs. 2,143 Cr., up from Rs. 1,831 Cr. in Q3’FY25 (approx. 17% YoY growth). Q3’FY26 Financials:.
From Jubilant Pharmova Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
2 more points from Jubilant Pharmova Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Expansion at Greater Noida & Bengaluru sites; new site Devanahalli, Bengaluru: capacity increasing from 1,000 FTEs (FY25) to 2,000 (FY28) to 4,000 (FY30); Total Capex USD 150 Mn; expected RoCE > 20%.
- New Isolator Fill & Finish Line (Line 5) at Montreal: construction started; Capex USD 114 Mn, concessional loan USD 35 Mn; production resumed Q4’FY26; technology transfer revenue expected FY29; target EBITDA breakeven FY28.
- Line 4 installation (Spokane): on track; technology transfer revenue to start Q4’FY27; full utilization in 3.5 years; peak revenue potential USD 80-90 Mn.
2 more points from Jubilant Pharmova Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- On Page 43, the presentation states: "Building a strong order book pipeline" for Line 4 installation.
- It also mentions expectation of technology transfer revenues to start in Q4’FY27.
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Jubilant Pharmova Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,122 | 1,822 | +16.5% | 1,966 | +7.9% |
| Operating profit (EBITDA) | 289 | 287 | +0.7% | 341 | -15.2% |
| Operating margin | 14% | 16% | -2 pp | 17% | -3 pp |
| Profit before tax | 93 | 130 | -28.5% | 190 | -51.1% |
| Net profit (PAT) | 56 | 101 | -44.6% | 120 | -53.3% |
| EPS (₹) | 3.51 | 6.33 | -44.5% | 7.55 | -53.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.4K Cr, net profit ₹31 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmo's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q3 FY26 results?
Q3’FY26 Total Income: Rs. 2,143 Cr., up from Rs. 1,831 Cr. in Q3’FY25 (approx. 17% YoY growth). Q3’FY26 Financials:.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
Expansion at Greater Noida & Bengaluru sites; new site Devanahalli, Bengaluru: capacity increasing from 1,000 FTEs (FY25) to 2,000 (FY28) to 4,000 (FY30); Total Capex USD 150 Mn; expected RoCE > 20%.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
